CCM
DTIL icon

Cinctive Capital Management’s Precision BioSciences DTIL Stock Holding History

Cinctive Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,625
Closed -$150K – 539
2022
Q1 		$150K Hold
1,625
– – 0.01% 458
2021
Q4 		$361K Sell
1,625
-875
-35% -$244K 0.02% 470
2021
Q3 		$866K Buy
+2,500
New +$847K 0.04% 420

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cinctive Capital Management's DTIL Position: Q2 2022 in Review

Cinctive Capital Management sold out of Precision BioSciences (DTIL) in Q2 2022, closing a stake of 1,625 shares — an estimated $150K sold.

Cinctive Capital Management first reported a position in DTIL in Q3 2021 and held it in 3 quarters. The position peaked at $866K in Q3 2021. 119 funds tracked by Wall St. Rank hold DTIL as of Q2 2022.

  • Cinctive Capital Management reported no remaining Precision BioSciences position as of Q2 2022 after selling out during the quarter.
  • Cinctive Capital Management sold 1,625 Precision BioSciences shares in Q2 2022, an estimated $150K.
  • Cinctive Capital Management first reported a position in Precision BioSciences in Q3 2021 and held it in 3 quarters.
  • Cinctive Capital Management's Precision BioSciences position peaked at $866K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2022.

Based on Cinctive Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.